Rapid analysis of GSTM1, GSTT1 and GSTP1 polymorphisms using real-time polymerase chain reaction

Pharmacogenetics

Volumn 10, Issue 3, 2000, Pages 271-274

  Ko, Y ^a   Koch, B ^a   Harth, V ^b   Sachinidis, A ^a   Thier, R ^c   Vetter, H ^a   Bolt, H M ^c   Bruning T ^c  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b Medizinisches Inst für U   (Germany)

^c LEIBNIZ RESEARCH CENTRE FOR WORKING ENVIRONMENT AND HUMAN FACTORS   (Germany)

Author keywords

GSTM1; GSTP1; GSTT1; Real time PCR

Indexed keywords

GLUTATHIONE TRANSFERASE; ISOENZYME; XENOBIOTIC AGENT;

ARTICLE; CANCER GENETICS; CONTROLLED STUDY; DNA HYBRIDIZATION; FLUORESCENCE; GENETIC EPIDEMIOLOGY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MULTIGENE FAMILY; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0034009993     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200004000-00009     Document Type: Article

References (11)

1. Bell DA, Taylor JA, Paulson DF, Robertson CN, Mohler JL, Lucier GW. Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J Natl Cancer Inst 1993; 85:1159-1164.
2. Chen CL, Liu Q, Relling MV. Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. Pharmacogenetics 1996; 6:187-191.
3. Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 1997; 18:641-644.
4. Harris MJ, Coggan M, Langton L, Wilson SR, Board PG. Polymorphism of the Pi class glutathione S-transferase in normal populations and cancer patients. Pharmacogenetics 1998; 8:27-31.
5. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995; 30:445-600.
6. Kerb R, Brockmöller J, Sachse C, Roots I. Direction of the GSTM1*0 allele by long polymerase chain reaction. Pharmacogenetics 1999; 9:89-94.
7. Kristensen VN, Andersen TI, Lindblom A, Erikstein B, Magnus P, Borresen-Dale AL. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics 1998; 8:43-48.
8. Miller MS, McCarver DG, Bell DA, Eaton DL, Goldstein JA. Genetic polymorphisms in human drug metabolic enzymes. Fundam Appl Toxicol 1997; 40:1-14.
9. Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, et al. Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 1994; 300:271-276.
10. Rebbeck TR. Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1997; 6:735-743.
11. Wormhoudt LW, Commandeur JN, Vermeulen NP. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol 1999; 29:59-124.